Dr. Goy Discusses Long-Term Follow-Up Results for Ibrutinib in MCL

December 14, 2017
Andre Goy, MD

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, Hackensack Medical Center, discusses long-term follow-up results for ibrutinib (Imbruvica) in relapsed/refractory mantle cell lymphoma.